Avance Biosciences is excited to announce its participation in the upcoming 2nd CRISPR-Based Therapy Analytical Development Summit, taking place from September 17-19, 2024, in Boston, MA. This premier event is a key gathering for professionals and innovators in the gene editing and CRISPR fields.
At the summit, our team will showcase our cutting-edge expertise in gene editing analysis, particularly focusing on on/off-target effects, which are crucial for the development of safe and effective CRISPR-based therapies. Our comprehensive services, including GUIDE-Seq, rhAmpSeq™, and advanced amplicon sequencing, are designed to ensure the precision and reliability of gene editing technologies.
Visitors to our booth will have the opportunity to learn more about our innovative approaches to on/off-target analysis and discuss how our solutions can enhance the development and safety of gene editing therapies. We invite all attendees to stop by and explore how Avance Biosciences can contribute to their CRISPR-based research and development efforts.
“We are thrilled to join this important event,” said Cal Froberg, Senior VP of Sales & Marketing at Avance Biosciences. “The summit provides an excellent platform to connect with industry leaders and share our advancements in CRISPR-based therapy analysis. Our goal is to support the development of safe and effective gene therapies through rigorous on/off-target analysis.”
For more information about the summit and our participation, please visit: https://crispr-analytical-development.com/.
We look forward to engaging with fellow researchers, scientists, and industry experts at this exciting event!
When you partner with Avance Biosciences™, you gain a CRO partner that is creative, collaborative and dedicated to sound science with a focus on the regulatory requirements our partners require. Contact our technical staff to discuss how we can support you in your project!
